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Abstract
Chronic kidney disease (CKD) is a worldwide public health problem that is associated with substantial morbidity and
mortality. To search for sequence variants that associate with CKD, we conducted a genome-wide association study
(GWAS) that included a total of 3,203 Icelandic cases and 38,782 controls. We observed an association between CKD and
a variant with 80% population frequency, rs4293393-T, positioned next to the UMOD gene (GeneID: 7369) on
chromosome 16p12 (OR = 1.25, P = 4.1610210). This gene encodes uromodulin (Tamm-Horsfall protein), the most
abundant protein in mammalian urine. The variant also associates significantly with serum creatinine concentration
(SCr) in Icelandic subjects (N = 24,635, P = 1.3610223) but not in a smaller set of healthy Dutch controls (N = 1,819,
P = 0.39). Our findings validate the association between the UMOD variant and both CKD and SCr recently discovered in
a large GWAS. In the Icelandic dataset, we demonstrate that the effect on SCr increases substantially with both age
(P = 3.0610217) and number of comorbid diseases (P = 0.008). The association with CKD is also stronger in the older age
groups. These results suggest that the UMOD variant may influence the adaptation of the kidney to age-related risk
factors of kidney disease such as hypertension and diabetes. The variant also associates with serum urea (P = 1.061026),
uric acid (P = 0.0064), and suggestively with gout. In contrast to CKD, the UMOD variant confers protection against
kidney stones when studied in 3,617 Icelandic and Dutch kidney stone cases and 43,201 controls (OR = 0.88,
P = 5.761025).
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Introduction
Chronic kidney disease (CKD) is a common disorder that can
progress to kidney failure and is associated with an increased risk
of cardiovascular disease and mortality [1,2]. The cause of CKD is
not always known and frequently appears multifactorial with
hypertension (HTN) and diabetes mellitus (DM) being the most
important causes [3–6]. Other causes include intrinsic kidney
disorders, atherosclerosis and nephrotoxic drugs [7,8]. Studies also
indicate a dramatic increase in the prevalence of CKD with
advancing age [9,10]. With greater lifespan, the burden of CKD is
thus steadily rising in the Western world [11], resulting in a
substantial impact on the health care system [12].
Previous studies have suggested a genetic contribution to the
risk of kidney disease. Heritability estimates of serum creatinine
(SCr) and estimated glomerular filtration rate based on SCr
(eGFRcrea), both common measures of kidney function, have
been reported as 29% and 33%, respectively [13]. Recently,
Ko¨ttgen et al. [14] published the first genome-wide association
study (GWAS) on eGFRcrea, eGFR based on cystatin C
(eGFRcys), another measure of kidney function, and CKD,
reporting significant association with eGFRcrea at three loci
(UMOD, SHROOM3 (GeneID: 57619) and GATM-SPATA5L1
(GeneIDs: 2628 and 79029)), with eGFRcys at two loci (CST3-
CST9 (GeneIDs: 1471 and 128822) and STC1 (GeneID: 6781))
and with CKD at one locus (UMOD) [14].
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With the aim of discovering sequence variants that associate
with kidney function, we conducted a GWAS in a total of 3,203
Icelanders with CKD and 38,782 controls and in 24,635 Icelandic
and 1,819 Dutch subjects with SCr information. We found a
sequence variant at the UMOD locus that associates with both
CKD and SCr at a genome wide-significant (GWS) level,
providing an independent replication of the result by Ko¨ttgen et
al [14]. We also show that this variant interacts with age-related
increase in SCr levels with little or no effect on SCr before the age
of 50 years, followed by a rapidly growing effect with increasing
age. We demonstrate that this variant associates significantly with
serum urea, uric acid and suggestively with gout. In contrast to the
deleterious effect on kidney function, the variant confers protection
against kidney stone disease.
Results/Discussion
Genome-wide association of variants at the UMOD locus
with CKD and SCr
A GWAS of 2.5 million SNPs, either directly genotyped
(Illumina HumanHap300 or HumanHapCNV370 bead chips) or
imputed based on the HapMap CEU samples [15], was performed
on a sample set of 2,903 Icelanders with CKD (see Materials and
Methods for sample set description) and 35,818 controls and also
on 22,256 Icelandic subjects with SCr information (See QQ-plots
in Figure S1 and Figure S2). The Icelandic SCr measurements
came from two laboratories; the Laboratory in Mjodd, a private
outpatient laboratory, and the Clinical Biochemistry Laboratory of
Landspitali University Hospital (LUH), serving both inpatients
and outpatients. These subjects had 5.2 SCr measurements on
average (geometric mean) and we used the median SCr value for
each individual in the subsequent analysis. The SCr values from
the two Icelandic laboratories showed similar dependence on age
and sex but there was clearly a trend towards higher SCr in the
hospital laboratory compared with the outpatient laboratory
(Figure S3).
The GWAS on CKD and SCr both yielded several SNPs in
high linkage disequilbrium (LD) on chromosome 16p12 with GWS
(P,561028) association to increased risk of CKD and elevated
SCr. For both phenotypes, this signal is tagged by rs4293393-T
(Table 1 and Table 2). For CKD, the odds ratio (OR) conferred by
rs4293393-T was 1.25 (95% CI = 1.16–1.34) with a corresponding
P value of 6.261029. In an attempt to replicate this finding,
rs4293393 was typed in additional 300 Icelandic subjects with
CKD and 2,964 controls. The association was nominally
significant in the replication sample set and the effect size
consistent with the initial observation (Table 1). The combined
OR for rs4293393-T in the two Icelandic CKD sample sets was
1.25 (95% CI = 1.17–1.35) and P= 4.1610210. The association
between SCr and rs4293393-T on 16p12 was very strong with an
effect of 1.86 mmol/L per allele carried and P= 6.7610220
(Table 2). To follow up on these results, we genotyped
rs4293393 in 2,379 additional Icelanders with SCr information,
significantly replicating the initially observed effect (P= 1.461025,
Table 2). Analysis of the combined Icelandic datasets showed a
strong GWS association between rs4293393-T and elevated SCr
(effect = 1.93 mmol/L per allele, 95% CI = 1.55–2.31 mmol/L;
P= 1.3610223). Our findings provide an independent replication
of the recently reported results by Ko¨ttgen et al [14] of an
association of this 16p12 locus with CKD and eGFRcrea. The
strongest SNP associations outside the UMOD region on
chromosome 16p12 are shown in Table S1 (for CKD) and Table
S2 (for SCr), respectively.
For further assessment, we tested rs4293393 in 1,819 Dutch
subjects with SCr information. These were healthy population-
based controls (see Materials and Methods for sample set
description) with SCr values substantially different from the
Icelandic measurements, generally showing lower values and
Table 1. Association of rs4293393-T with chronic kidney disease (CKD).
CKD N Frequency
population case control case control OR (95% CI) P
Icelandic discovery 2,903 35,818 0.831 0.798 1.25 (1.16, 1.34) 6.261029
Icelandic replication 300 2,964 0.840 0.798 1.33 (1.05, 1.68) 0.019
Icelandic combined 3,203 38,782 0.832 0.798 1.25 (1.17, 1.35) 4.1610210
YOB$1950 143 38,782 0.811 0.798 1.09 (0.81, 1.46) 0.57
1950.YOB$1940 355 38,782 0.821 0.798 1.16 (0.96, 1.41) 0.12
1940.YOB$1930 1,029 38,782 0.834 0.798 1.28 (1.14, 1.43) 3.1N1025
1930.YOB$1920 1,242 38,782 0.838 0.798 1.31 (1.18, 1.46) 4.1N1027
1920.YOB 434 38,782 0.825 0.798 1.19 (1.00, 1.42) 0.045
Association of rs4293393-T with CKD in Icelandic subjects. Association is shown for the discovery sample set, the replication sample set, the combined Icelandic sample,
and finally, for the combined sample stratified by year of birth (YOB) as a proxy for age at onset.
doi:10.1371/journal.pgen.1001039.t001
Author Summary
Chronic kidney disease (CKD) is a common condition that
is associated with substantial morbidity and mortality and
has been recognized as a major public health problem
worldwide. Common causes of CKD include hypertension,
diabetes, and inflammatory disorders. Previous studies
have shown a significant genetic contribution to kidney
disease and a recent genome-wide association study
yielded a variant in the UMOD gene that affects the risk
of CKD. Here, we replicate the association between UMOD
and CKD in an independent analysis. We also demonstrate
for the first time an interaction between the UMOD variant
and age that suggests that this variant may adversely
affect the aging kidney and its adaptation to age-related
risk factors of kidney disease, such as hypertension and
diabetes. Furthermore, we show that the UMOD variant
that affects risk of CKD also provides protection against
kidney stone disease.
Variants Associating with CKD and Kidney Stones
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much less variability (Figure S3). Interestingly, no association was
observed in the 1,819 healthy Dutch subjects (effect = 0.38 mmol/
L, 95%CI =20.48–1.25 mmol/L; P= 0.39) (Table 2). Significant
heterogeneity was observed between the SCr association results for
the Icelandic and Dutch populations (I2 = 90.4%, P= 0.0013).
The SNP rs4293393 is located 550 basepairs upstream of
UMOD, encoding uromodulin, also known as the Tamm-Horsfall
protein (Figure 1). The protein is a glycosylphosphatidylinositol
(GPI)-anchored glycoprotein, exclusively expressed in the thick
ascending loop of Henle [16] and distal convoluted tubule [17] of
the mammalian kidney. It is the most abundant protein in urine of
healthy individuals, where it is present in a highly aggregated state
[18,19]. While the exact physiological function of uromodulin
remains to be elucidated, it has the capacity to bind to a variety of
ligands. It has been reported to prevent bacteria from adhering to
human kidney cells [20] and to inhibit calcium oxalate
crystallization [21]. It may also have a role in ion transport and
immunological processes [22,23]. UMOD knockout mice have
been shown to have decreased creatinine clearance [24] and
predilection for both urinary tract infections [25] and calcium
oxalate stone formation [26].
The rs4293393 variant is in perfect LD in the HapMap CEU
samples [15] with a synonymous SNP in UMOD, rs13335818,
coding for V264V (D9= 1.0, r2 = 1.0). The same perfect correla-
tion between rs4293393 and rs13335818 was observed in a set of
3,364 Icelanders (D9= 1.0, r2 = 1.0). Both rs4293393 and
rs13335818 are also in perfect correlation with rs12917707
(D9= 1.0, r2 = 1.0 for both markers in the HapMap CEU samples
[15]) near the UMOD, the variant reported by Ko¨ttgen et al [14]
to associate with both CKD and eGFRcrea with similar effect,
indicating that these SNPs are tagging the same signal. As
rs4293393 is on the Illumina 300/370K chips we used for direct
genotyping, we refer to rs4293393 in the remainder of this article.
The effect of the UMOD variant on SCr is age-dependent
Given that SCr varies substantially with both age and sex, we
tested for an interaction between the effect of rs4293393-T and
effects of age and sex on SCr. No interaction was found between
the UMOD variant and sex (P= 0.41). In contrast, a strong
interaction was observed between the UMOD variant and age in
the Icelandic sample set (P= 3.061017). On average, SCr
increased by an additional 0.09 mmol/L per year per allele of
rs4293393-T (95% CI = 0.07–0.11). In order to visualize this
interaction, we stratified our Icelandic samples based on age and
Table 2. Association of rs4293393-T with serum creatinine
concentration (SCr).
SCr sample N Effect (95% CI) P
Icelandic discovery 22,256 1.86 (1.46, 2.25) 6.7610220
Icelandic replication 2,379 2.68 (1.47, 3.89) 1.461025
Icelandic combined 24,635 1.93 (1.55, 2.31) 1.3610223
Dutch replication 1,819 0.38 (20.48, 1.25) 0.39
Association of rs4293393-T with SCr in Icelandic and Dutch subjects. Association is
shown for the discovery sample set, the Icelandic and Dutch replication sample
sets and the combined Icelandic sample. The population frequency of rs4293393-T
is 0.80 in Iceland and 0.81 in the Netherlands. Effects are given in mmol/L.
doi:10.1371/journal.pgen.1001039.t002
Figure 1. An overview of the region around rs4293393. Shown are the 2log10 association P values of SNPs in the region with CKD (black
circles), the SNPs’ build 36 coordinates, the genes in the region and their exons (in blue), and recombination rates in centimorgans (cM) per
megabase (Mb) (pink histogram).
doi:10.1371/journal.pgen.1001039.g001
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sex and tested for association within each stratum (Figure 2A).
Interestingly, rs4293393-T has little or no effect on SCr before the
age of 50 years, but thereafter the effect increases rapidly with
advancing age, especially around 70 years. Thus, the variant does
not affect SCr in young individuals but rather how SCr increases
with age. We note that due to the relatively short time span in
which the SCr data were collected there is an inherent
confounding between age and generation in our study, which will
require further investigation to resolve. Similar interaction
between the UMOD variant, age and CKD was also observed
when the association analysis for CKD was stratified by year of
birth used here as a proxy for age of onset (Table 1).
Although it is well known that kidney function declines with age,
GFR has been shown to decrease more slowly with senescence in
healthy individuals than previously thought [3–5,11]. Comorbid
conditions that increase in frequency with aging, including HTN,
DM, atherosclerosis and heart failure are, however, increasingly
recognized as important contributors of age-related decline in kidney
function [3,4,6–8]. We thus proceeded to investigate whether the age
effect observed in carriers of the UMOD variant is influenced by
interaction with age-related risk factors for decline in kidney function.
UMOD-associated increase in SCr with age is affected by
the number of comorbid conditions present
As HTN, type 2 DM and atherosclerosis are all well recognized
age-dependent risk factors for CKD [3,4,6–8], the association
analysis was repeated after stratifying the SCr data based on these
conditions. Incomplete information regarding history of HTN
(5,705 cases), type 2 DM (1,422 cases) and myocardial infarction
(MI, 2,551 cases) was available for the Icelandic SCr sample set. In
parallel with previous studies, the rate of increase in SCr with age
was significantly higher in individuals with HTN than in
individuals without this diagnosis (effect = 0.23 mmol/L/year,
95% CI = 0.19–0.26 mmol/L/year; P= 2.9610235). Similar re-
sults were obtained for type 2 DM (effect = 0.26 mmol/L/year,
95% CI = 0.19–0.34 mmol/L/year; P= 1.1610211) and MI (ef-
fect = 0.36 mmol/L/year, 95% CI = 0.30–0.42 mmol/L/year;
P= 1.4610232) as well as the number of comorbid conditions
(Figure 2B). We also found that the effect of rs4293393-T on SCr
increases with the number of comorbid conditions present
(Figure 2C).
To further assess the relationship between genotype, age and
risk factors for reduced kidney function, we investigated the effect
of the rs4293393-T allele count on the increase in SCr with age
stratifying on HTN and type 2 DM. A trend was observed for a
higher rate of increase in SCr with age and rs4293393-T allele
count in individuals with HTN compared to those without a
diagnosis of HTN (P= 0.077) as well as in those with type 2 DM
compared to those without (P= 0.063). In other words, the age-
related increase in SCr levels appears to be greater in rs4293393-T
carriers that have either HTN or type 2 DM than in carriers who
do not have these risk factors. However, an age effect was still
observed after accounting for these age-related risk factors.
Furthermore, we also observed a significantly higher rate of SCr
increase with age and rs4293393-T allele count stratifying on the
number of comorbid conditions present (P= 0.0080) (Figure 2D).
To determine whether rs4293393-T influenced kidney function
by directly affecting known risk factors, we tested the association of
rs4293393-T in well powered Icelandic case-control sets of HTN,
MI, stroke, and type 2 DM (Table S3). A weak nominally
significant association of rs4293393-T with increased risk of HTN
was observed (OR = 1.07, 95% CI = 1.01–1.12; P= 0.014), but not
with the other diseases tested. These data demonstrate that the
effect of rs4293393-T on kidney function is not mediated through
increased risk of these comorbid conditions, but rather suggest that
the variant may affect the vulnerability of the kidney to these risk
factors.
These findings, demonstrating not only the effect of age on
UMOD-associated increase in SCr but also the effect of age-related
comorbid conditions, may explain why no association was
observed between rs4293393-T and kidney function in the Dutch
sample set of healthy population-based subjects with much lower
SCr values and of much less variability than observed in the
Icelandic samples (Figure S3).
Association of the UMOD variant with serum urea
Urea is another small solute that is commonly used to assess
renal function together with SCr. The correlation between SCr
and serum urea in our data was 58%. We tested for association
between rs4293393-T and serum urea in an Icelandic sample set
that had urea measurements performed at the Laboratory in
Mjodd (N = 4,084) and found significant association with increased
serum urea concentration (effect = 0.36 mg/dL, 95% CI = 0.23–
0.50 mg/dL; P= 1.061026).
Association of the UMOD variant with uric acid and gout
In humans, rare mutations in the UMOD gene that cause
accumulation of abnormal uromodulin in the nephron and
reduced urinary excretion of the normal protein [27] have been
associated with two autosomal dominant kidney diseases with
overlapping clinical features, medullary cystic kidney disease and
familial juvenile hyperuricemic nephropathy [28]. These disorders
are characterized by hyperuricemia, gout and progressive renal
failure due to tubulointerstitial nephropathy. Given the link
between UMOD and hyperuricemia, we tested rs4293393-T in
Icelandic subjects with serum uric acid values from the Laboratory
in Mjodd (N = 6,583) and observed significant association
(effect = 6.1, 95% CI = 1.7–10.4; P= 0.0064). We then tested for
association with gout in a set of 377 Icelandic cases and 39,916
controls (see Materials and Methods for sample set description)
and found a suggestive association (OR = 1.17, 95% CI = 0.97–
1.41; P= 0.097). These data contrast the work of Ko¨ttgen et al
[14] that neither detected association with serum uric acid nor
gout.
Reduced risk of kidney stone formation in carriers of the
UMOD CKD risk variant
As uromodulin is thought to prevent the formation of calcium-
containing kidney stones [21], we tested rs4293393 in a sample set
of 1,689 Icelandic patients with radiopaque kidney stones and
37,076 Icelandic population controls. We observed a significant
association between rs4293393-T and reduced risk of kidney
stones (OR = 0.88, 95% CI = 0.81–0.96; P= 0.0053). In an
attempt to replicate this observation, we genotyped rs4293393 in
two additional sample sets of European ancestry, one from Iceland
(1,271 cases and 3,177 controls) and the other from the
Netherlands (701 cases and 2,948 controls) (Table 3). The effect
size in both replication samples is consistent with the initial
observation and the association is significant in the combined
replication samples (OR = 0.89, 95% CI = 0.81–0.97; P= 0.0089).
There was no correlation between the effect size and year of birth
of the kidney stone patients (Table S4).
Replication of the SHROOM3 and GATM-SPATA5L1
eGFRcrea loci and the STC1 and CST3-CST9 eGFRcys loci
Ko¨ttgen et al [14] reported on variants at additional loci with
GWS association to eGFRcrea (SHROOM3 and GATM-SPA-
Variants Associating with CKD and Kidney Stones
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Figure 2. An overview of the effect of age and the number of comorbid conditions on SCr levels, directly and through the
rs4293393-T allele count. (A) The effect of rs4293393-T on SCr stratified on age and sex. (B) The mean SCr stratified by the number of comorbid
conditions and sex, compared to the mean SCr in those without any comorbid conditions. (C) The effect of rs4293393-T on SCr stratified by the
Variants Associating with CKD and Kidney Stones
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TA5L1) or eGFRcys (STC1 and CST3-CST9). We tested these
variants in our Icelandic datasets, including a small sample set with
cystatin C measurements (Table 4). The association with SCr
replicated for both the SHROOM3 and GATM-SPATA5L1 SNPs
(P= 0.00057 and P= 0.0067, respectively) and the association with
cystatin C replicated for the CST3-CST9 SNP but not the STC1
SNP (P= 0.00037 and P= 0.73, respectively). It should be noted,
however, that the Icelandic cystatin C sample set is very small
(N = 284) and possibly underpowered to replicate the reported
association with the STC1 SNP. The STC1 SNP did show
association with SCr in our dataset (P= 1.6?1026) as was observed
in the analysis by Ko¨ttgen et al [14]. The SHROOM3 and GATM-
SPATA5L1 SNPs showed suggestive association with CKD in the
analysis by Ko¨ttgen et al [14] and our data support this association
but do not constitute a conclusive replication. In contrast to the
UMOD variant, we did not observe an interaction between the
variants at these other loci and age. Furthermore, none of the
SNPs did associate with kidney stones in Iceland (data not shown).
Finally, Ko¨ttgen et al [14] reported suggestive association between
eGFRcrea and variants at JAG1 (GeneID: 182); we did not
replicate this finding in our SCr scan (for rs6040055-T:
effect =20.27, 95% CI =20.6020.05), P= 0.17).
In summary, we describe sequence variants next to and in
UMOD that associate with increased risk of CKD and elevated
SCr but confer protection against kidney stones. We also
demonstrate an interaction between these variants and both age
and comorbid conditions that are related to decline in kidney
function. Our observations indicate that UMOD is important for
maintaining kidney function with advancing age and exposure to
risk factors that are associated with aging, such as HTN, type 2
DM and cardiovascular disease.
Materials and Methods
Study subjects from Iceland
Landspitali University Hospital (LUH) is a regional hospital for
the greater Reykjavı´k area and a tertiary referral center for the
entire Icelandic nation. The population of Iceland is comprised of
330,000 inhabitants of whom approximately 200,000 reside in the
greater Reykjavik area. The nation’s only nephrology clinic is
located at LUH and all laboratory tests for the primary care clinics
of the greater Reykjavik area are performed in the hospital’s
laboratories. We obtained results of all SCr measurements
performed during the period 2003 to 2008 from the computerized
database of the Clinical Laboratories at LUH and used the SCr
values to identify those with chronic kidney disease (CKD) based
on calculation of the estimated glomerular filtration rate (eGFR)
by the original 4-variable Modification of Diet in Renal Disease
(MDRD) study equation. We classified those with eGFR,60 ml/
min/1.73 m2 as having CKD. All individuals with acute kidney
injury and those who had eGFR,60 ml/min/1.73 m2 of less than
3 months duration were excluded from the CKD sample set. The
study included CKD patients that had donated blood through
various genetic programs at deCODE genetics.
Biochemical measurements including SCr, serum urea, serum
uric acid and serum cystatin C were available from two
laboratories, the Laboratory in Mjodd, Reykjavik, Iceland, a
private outpatient laboratory, and the Clinical Biochemistry
Laboratory of LUH, serving both inpatients and outpatients.
The main referral center for the Laboratory in Mjodd is a
multispecialty medical clinic in Reykjavik (Laeknasetrid). The
laboratory tests were done in the years 1997–2008 at the
Laboratory in Mjodd and in the years 2003–2008 at LUH. The
Icelandic SCr measurements came from both laboratories, the
Laboratory in Mjodd (N = 10,260) and LUH (N = 22,898, of
whom 8,523 also had measurements from the Laboratory in
Mjodd). At the LUH, the same enzymatic method was used for
measurement of SCr during the study period (Vitros 950
Autoanalyzer, Ortho Clinical Diagnostics, Rochester, MN,
USA), whereas at the Laboratory in Mjodd, SCr measurements
were performed by modified kinetic Jaffe rection assays until May
2007 when an enzymatic method was introduced.
The Icelandic kidney stone cases consisted of patients with
confirmed radiopaque kidney stones from the Icelandic Kidney
Stone Disease Registry at LUH. The study included kidney stone
patients that had donated blood through various genetic programs
at deCODE genetics.
The coronary artery disease [29], stroke [30] and type 2 DM
[31,32] patient groups from Iceland have been described
previously. The HTN sample set includes individuals who have
been recruited into various genetic programs at deCODE and
have: (1) self-reported HTN; (2) received the diagnosis of HTN at
discharge from the LUH; or (3) have attended the Hypertension
Clinic at LUH. The gout sample set includes subjects who were
Table 3. Association of rs4293393-T with kidney stones.
Kidney stone N Frequency
population case control case control OR (95% CI) P
Icelandic discovery 1,689 37,076 0.781 0.801 0.88 (0.81, 0.96) 0.0053
Icelandic replication 1,271 3,177 0.786 0.801 0.91 (0.81, 1.03) 0.13
Icelandic combined 2,916 40,253 0.782 0.801 0.89 (0.83, 0.95) 0.00075
Dutch replication 701 2,948 0.782 0.810 0.85 (0.73, 0.98) 0.022
Combined 3,617 43,201 - - 0.88 (0.83, 0.94) 5.761025
Association of rs4293393-T with kidney stone disease in Icelandic and Dutch subjects. Association is shown for the discovery sample set, the Icelandic and Dutch
replication sample sets, the combined Icelandic sample, and all the sample sets combined.
doi:10.1371/journal.pgen.1001039.t003
number of comorbid conditions and sex. (D) The interaction effect between age and rs4293393-T allele count on SCr stratified by the number of
comorbid conditions and sex. The circles give the point estimates and the vertical lines show their 95% confidence intervals. Estimates and
confidence intervals are given in blue for males and red for females. Sample sizes (N) are given for each strata for males and females, respectively.
Effects are given in mmol/L in (A–C) and mmol/L/year in (D).
doi:10.1371/journal.pgen.1001039.g002
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recruited into various genetic programs at deCODE and reported
the use of either one of two specific anti-gout medications,
allopurinol or colchicine.
The Icelandic controls used in the case-control genome-wide
association studies (GWAS) and replication studies were selected
among individuals who had participated in the various genetic
programs at deCODE genetics; tremor, preeclampsia, endome-
triosis, psoriasis, type 2 DM, Alzheimer’s disease, osteoarthritis,
schizophrenia, peripheral artery disease, abdominal aortic aneu-
rysm, chronic obstructive pulmonary disease, stroke, osteoporosis,
coronary artery disease, HTN, asthma, Parkinson’s disease, sleep
apnea, age-related macular degeneration, polycystic ovary syn-
drome, rheumatoid arthritis, lung cancer, longevity, benign
prostatic hyperplasia, enuresis, migraine, glaucoma, attention
deficit hyperactivity disorder, prostate cancer, infectious diseases,
anxiety, expression studies, autism, dyslexia, melanoma, colorectal
cancer, deep vein thrombosis, restless leg syndrome, studies on
addiction and population controls. Individuals who reported a
history of the trait being tested (e.g. CKD) were excluded from the
control set. Some of the controls participated in more than one
genetic program in which case their genotypes are only included
once.
The study was approved by the Icelandic Data Protection
Authority and the National Bioethics Committee. All patients
signed informed consent and donated blood samples. Personal
identities of the patients and biological samples were encrypted by
a third party system provided by the Icelandic Data Protection
Authority.
Study subjects from The Netherlands
All samples with SCr measurements came from the Nijmegen
Biomedical Study. The details of this study have been reported
previously [33]. Briefly, this is a population-based survey
conducted by the Department of Epidemiology and Biostatistics
and the Department of Clinical Chemistry of the Radboud
University Nijmegen Medical Center (RUNMC), in which 9,371
individuals participated from a total of 22,500 age- and sex-
stratified, randomly selected inhabitants of Nijmegen. The subjects
were invited to participate in a study on gene-environment
interactions in complex diseases. All participants filled out a
questionnaire on lifestyle and medical history at baseline and 6500
of them donated blood samples for DNA isolation and
biochemical studies. A fraction of the study participants were
previously genotyped with the Illumina HumanHap300 or
HumanHapCNV370 bead chips; these were selected to serve as
controls in GWAS on prostate and breast cancer and were selected
primarily based on age. A total of 1,819 individuals had both
serum creatinine measurements and genome-wide SNP data
available for analysis in this study.
The Dutch patients with kidney stones were recruited from two
sources: The outpatient clinics of the RUNMC and The Nijmegen
Biomedical Study. All patients who present to the outpatient
clinics of the RUNMC are invited to participate in a study on the
effects of genes and lifestyle on the development of urological
diseases. In case of consent, the patients fill out a questionnaire on
lifestyle and donate a blood sample for DNA isolation. The
controls for the analysis of kidney stone disease were also taken
from the biobank of the Nijmegen Biomedical Study. All patients
and controls were of self-reported European descent and were fully
informed about the goals and the procedures of these studies. The
study protocols for the recruitment of patients from outpatient
clinics and the recruitment of participants to the Nijmegen
Biomedical Study were approved by the RUNMC Institutional
Review Board. All study subjects gave written informed consent.
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Illumina genome-wide genotyping
All Icelandic case and control samples were assayed with the
Illumina HumanHap300 or HumanHapCNV370 bead chips
(Illumina, SanDiego, CA, USA), containing 317,503 and
370,404 haplotype tagging SNPs derived from phase I of the
International HapMap project, respectively. Only SNPs present
on both chips were included in the analysis and SNPs were
excluded if they had: (a) yield lower than 95% in cases or controls;
(b) minor allele frequency less than 1% in the population; or (c)
showed significant deviation from Hardy-Weinberg equilibrium in
the controls (P,0.001). Any samples with a call rate below 98%
were excluded from the analysis. The final analysis included
302,379 SNPs.
Imputation of SNP genotypes
The genome-wide association scan was based on expected allele
counts obtained with the IMPUTE software [34], using the HapMap
CEU samples as a training set [15]. The test for association was then
performed using the expected allele counts as covariates. The
imputation information was estimated by the ratio of the observed
likelihood of allele counts and the likelihood of allele counts assuming
perfect information under the assumption of Hardy-Weinberg
equilibrium. The estimated information for the four SNPs imputed
in Table 4 was high in all instances (.0.96).
Single SNP genotyping
Single SNP genotyping of all samples was carried out at
deCODE genetics in Reykjavik, Iceland, applying the same
platform to all populations studied. All single SNP genotyping was
carried out using the Centaurus (Nanogen) platform [35]. The
quality of each Centaurus SNP assay was evaluated by genotyping
each assay on the CEU samples and comparing the results with
the HapMap data. All assays had a mismatch rate ,0.5%.
Additionally, all markers were re-genotyped on more than 10% of
samples typed with the Illumina platform resulting in an observed
mismatch in less than ,0.5% of samples.
Association analysis
For case-control association analysis, e.g. for CKD and kidney
stones, we utilized a standard likelihood ratio statistic, implement-
ed in the NEMO software [32] to calculate two-sided P values and
odds ratios (ORs) for each individual allele, assuming a
multiplicative model for risk, i.e. that the risk of the two alleles
carried by a person multiplies [36]. Allelic frequencies, rather
than carrier frequencies, are presented for the markers and P
values are given after adjustment for the relatedness of the
subjects. When estimating genotype specific OR, genotype
frequencies in the population were estimated assuming Hardy-
Weinberg equilibrium.
Results from multiple case-control groups were combined using
a Mantel-Haenszel model [37] in which the groups were allowed
to have different population frequencies for alleles, haplotypes and
genotypes but were assumed to have common relative risks.
For the quantitative trait association analysis, e.g. for SCr and
cystatin C, we utilized a robust linear regression based on an M
estimator [38] as implemented in the rlm function of the R
software package [39]. An additive model for SNP effects was
assumed in all instances. All associations with quantitative traits
were performed adjusting for age and sex.
Estimation and testing of interaction effects
Interaction effects were tested by assuming all main effects and
lower order interaction effects were present under the null model
but not the interaction effect, resulting in a one degree of freedom
model. For example, when testing for an interaction effect on SCr
between age and the rs4293393-T allele count, the null model
included as covariates age, sex and the rs4293393-T allele count.
The alternative model included all these covariates as well as the
product of the interaction of age and the rs4293393-T allele
counts. Similarly, when testing for the interaction between age, the
number of comorbid conditions and the rs4293393-T allele count,
the null model included as covariates age, sex, rs4293393-T allele
count, the product of interaction of age and rs4293393-T allele
count, the product of interaction of the number of comorbid
conditions and rs4293393-T allele count, and the product of
interaction of age and the number of comorbid conditions and the
alternative model added the product of interaction of age, the
rs4293393-T allele count and the number of comorbid conditions.
In the instances when an interaction effect was estimated, the main
effect estimates and P values shown were obtained from fitting the
appropriate model without an interaction effect.
Correction for relatedness of the subjects and genomic
control
Some of the individuals in the Icelandic patient and control
groups are related to each other, causing the chi-square test
statistic to have a mean .1 and median .0.675. We estimated the
inflation factor for the genome-wide association by calculating the
average of the 302,379 chi-square statistics, which was a method of
genomic control [40] to adjust for both relatedness and potential
population stratification. The inflation factor was estimated as 1.15
for CKD and 1.22 for SCr and all the results presented from
association with these traits were adjusted based on these inflation
factors.
Supporting Information
Figure S1 QQ plot of 2.5 million SNPs in the genome-wide
association scans for chronic kidney disease. The black dots
represent the observed P values and the blue ‘x’s represent the P
values scaled down by an inflation factor estimated using genomic
control (1.15). The diagonal red line represents where the dots are
expected to fall under the null hypothesis of no association. The
horizontal green line represents the threshold for genome-wide
significance.
Found at: doi:10.1371/journal.pgen.1001039.s001 (0.69 MB TIF)
Figure S2 QQ plot of 2.5 million SNPs in the genome-wide
association scans for serum creatinine. The black dots represent
the observed P values and the blue ‘x’s represent the P values
scaled down by an inflation factor estimated using genomic control
(1.22). The diagonal red line represents where the dots are
expected to fall under the null hypothesis of no association. The
horizontal green line represents the threshold for genome-wide
significance.
Found at: doi:10.1371/journal.pgen.1001039.s002 (0.69 MB TIF)
Figure S3 The observed distribution of SCr measurements in
Iceland and the Netherlands. The measurements from Iceland
come from the Laboratory in Mjodd and the Clinical Biochem-
istry Laboratory of Landspitali University Hospital (LUH). The
red line denotes the population median and the two dashed blue
lines the 5% and 95% quantiles. Measurements above 200 are
lumped together for visualization purposes. The unit of measure-
ment is mmol/L.
Found at: doi:10.1371/journal.pgen.1001039.s003 (0.05 MB EPS)
Table S1 Strongest SNP associations (P,2?1025) with CKD
outside the UMOD region on chromosome 16p12.
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Found at: doi:10.1371/journal.pgen.1001039.s004 (0.05 MB
DOC)
Table S2 Strongest SNP associations (P,1026) with SCr outside
the UMOD region on chromosome 16p12.
Found at: doi:10.1371/journal.pgen.1001039.s005 (0.10 MB
DOC)
Table S3 Association of rs4293393-T with risk factors of kidney
function decline in Icelandic case-control groups.
Found at: doi:10.1371/journal.pgen.1001039.s006 (0.03 MB
DOC)
Table S4 Results of age-specific association for rs4293393-T and
kidney stones using year of birth (YOB) as a proxy for age at onset.
Found at: doi:10.1371/journal.pgen.1001039.s007 (0.03 MB
DOC)
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